BRAIN Biotech AG Pioneering the biologization of industry
A leading European specialist in industrial biotechnology developing bio-based products and solutions for nutrition, health, and the environment supporting a more sustainable, circular economy.
BRAIN Biotech AG Investor Relations Video Hub
All CEO & CFO video presentations from BRAIN Biotech AG filter by format below to find what you need.
BRAIN Biotech AG Elevator Pitch | Enzymes, Bioeconomy & Innovation
BRAIN Biotech Elevator Pitch with CFO Michael Schneiders. Learn about industrial biotechnology, specialty enzymes, BioIncubator, and the company's Top 10 growth ambition.
Watch presentation
BRAIN Biotech AG Financial Results 9M 2025 / 26 | Enzymes, BioIncubator & Outlook
Watch
BRAIN Biotech AG Company Presentation | Specialty Enzymes, BioIncubator & Growth Strategy
Watch
BRAIN Biotech AG Financial Results H1 2025 / 26 | Enzymes, CRISPR, BioIncubator Projects
Watch
BRAIN Biotech AG Financial Results FY 2024 / 25 | Monetization, Margins & Enzyme growth initiatives
Watch
BRAIN Biotech AG Deep Dive | AI-Driven Enzyme Discovery, U.S. Expansion, and Growth Strategy Explained
Watch
BRAIN Biotech AG Financial Results 9M 2024 / 25 | Strong Core Growth & BioIncubator Innovations
Watch
BRAIN Biotech AG Elevator Pitch | Strategy & Vision
Watch
BRAIN Biotech AG Financial Results H1 2024 / 25 | Momentum & Strategic Focus
Watch
BRAIN Biotech AG Financial Results Q1 2024 / 25 | Growth, Innovation & Outlook
Watch
BRAIN Biotech AG Financial Results FY 2023 / 24 | Financial Performance and Growth Strategy with CFO
Watch
BRAIN Biotech AG Financial Results 9M 2023 / 24 | Strategic Growth in Challenging Economy
Watch
BRAIN Biotech AG Financial Results H1 2023 / 24 | Robust Results and Strategic Outlook
Watch
BRAIN Biotech AG Elevator Pitch 2025 | Strategie und Visionen (Deutsche Version)
Watch
BRAIN Biotech AG Financial Results Q1 2023 / 24 | Strategic Financial Outlook
Watch
BRAIN Biotech AG Financial Results 9M 2022 / 23 | Journey to Sustainability & Prosperity
Watch
BRAIN Biotech AG Financial Results H1 2022 / 23 | Steady Growth, Strategy, and Future Outlook
Watch
BRAIN Biotech AG Deep Dive | Revolutionizing the Food & Healthcare Industries
Watch
BRAIN Biotech AG Financial Results Q1 2022 / 23 | Revenue and Cash Improved
Watch
BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects
Watch
BRAIN Biotech AG Financial Results 9M 2021/ 22 | Unveiling the Future
Watch
BRAIN Biotech AG ESG | Targets, Opportunities and Key Points
Watch
BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets
Watch
BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals & Growth Trajectory
Watch
BRAIN Biotech AG Financial Results FY 2020 / 21 | Innovations, and Sustainability Commitments
Watch
BRAIN Biotech AG Deep Dive | Unlocking the Power of Biotechnology
Watch
BRAIN Biotech AG Company Presentation | Pioneering the Future of Industrial Biotechnology
Watch
BRAIN Biotech AG Elevator Pitch | Transforming Industries with Biotechnology
Watch
BRAIN Biotech AG Deep Dive | CRISPR Cas9 Opportunity
Watch
Driving the biologization of industry for a sustainable economy
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group, headquartered in Zwingenberg, Germany, with production facilities in Germany, the UK and the US.
Two Business Segments: BioScience & BioIndustrial
Two pillars form the BRAIN Group's business. The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. The BioIndustrial segment focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and their respective distribution to customers worldwide.
BRAIN Bioarchive and Technology Portfolio
The BRAIN Group maintains its own diverse collection of natural resources the BRAIN Bioarchive, comprising microorganisms, genetic material and natural substances. Built on this collection and a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in industry. Proprietary production facilities and biotechnological production expertise complete the value chain within the Group.
Commitment to Sustainability and Capital Markets
As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and to taking actions that advance broader societal goals. Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Want your company
on seat11a?
Join BRAIN Biotech and 100+ listed companies reaching institutional investors through CEO and CFO video presentations.